Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482696 | 0.88 | HDAC6 (0.67) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL22483036 | 0.87 | HDAC6 (0.67) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL29671340 | 0.82 | APLNR (0.61) | HDAC8HDAC6HDAC11 | |
| SCHEMBL24472769 | 0.82 | HDAC6 (0.77) | HDAC8HDAC3HDAC6HDAC11 | |
| SCHEMBL24472883 | 0.80 | HDAC8 (0.59) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL31034527 | 0.77 | TAS2R14 (0.60) | HDAC8HDAC6HDAC11 | |
| SCHEMBL29665682 | 0.77 | APLNR (0.54) | HDAC8HDAC6HDAC11 | |
| SCHEMBL31034579 | 0.77 | HDAC6 (0.52) | HDAC8HDAC3HDAC6HDAC11 | |
| SCHEMBL27020194 | 0.76 | TAS2R14 (0.59) | HDAC8HDAC6HDAC11 | |
| SCHEMBL22482886 | 0.76 | HDAC6 (0.69) | HDAC8HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169598-A1 | HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS | 2681603 ONTARIO INC. (CA) | 2022-06-02 | — | — | US | disclosed |
| WO-2020194272-A1 | HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS | 2681603 ONTARIO INC. (CA) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169598-A1 | HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC11 | HDAC8 11/4885HDAC3 4/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.